Barrier Therapeutics Launches Denavir(R) (Penciclovir Cream) in Canada
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Barrier Therapeutics Launches Denavir(R) (Penciclovir Cream) in Canada

The Only Topical Antiviral Rx Product Approved in Canada for the Treatment of Cold Sores

PRINCETON, NJ -- August 23, 2006 -- Barrier Therapeutics, Inc., a pharmaceutical company developing and commercializing products in the field of dermatology, today announced the commercial launch of Denavir® (penciclovir cream) 1% in Canada. Denavir is a topical antiviral prescription medication indicated for the treatment of herpes labialis, also known as cold sores, in adults. This is the only topical antiviral product available by prescription for treating this condition.

Cold sores are caused by a virus known as herpes simplex type 1 (HSV1) and typically appears on the outside of the mouth, usually on the face or around the lips. Cold sores are often a re-occurring condition and approximately 25% of those afflicted by cold sores experience at least three occurrences per year. The virus can be highly contagious and spread from person to person in a variety of ways including sharing eating utensils or close skin contact.

Specially formulated for use on the lips and face, Denavir is a non-greasy cream that contains an antiviral agent, penciclovir, which is active against the HSV1 virus. Denavir works by penetrating the area to block the virus that causes the cold sores and can help heal them on average in four and a half days. Denavir can also be effective in preventing the spread of the virus even after the cold sore blister has appeared.

With the launch of Denavir, physicians in Canada now have available a unique treatment option for patients who suffer from cold sores that has not been previously available.

SOURCE: Barrier Therapeutics, Inc.

E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities